Moderna raising its 2021 production target to at least 600 million doses and is working with partners to boost capacity for deliveries outside the US.
South Korea and the COVID-19 vaccine maker Moderna are in discussions over a $200m investment by the US drugmaker to build a vaccine manufacturing factory in the country, a former government minister who was involved in the talks said.
The news comes as the government also announced on Friday that it has approved pharmaceutical company Celltrion’s anti-COVID-19 treatment for conditional use.
Park Young-sun, who stepped down last month as minister for SMEs and Startups to run for Seoul mayor, made the comments about Moderna in an interview with the Asia Business Daily newswire.
She also said Moderna was highly interested in the Asian market, according to the report.
Her campaign official confirmed the report to the Reuters news agency. Moderna did not immediately respond to a request for comment.
“Moderna has expressed its interest to invest $200m … and I’ll continue to participate in the discussion for a while, as I had held talks with them as a minister,” Park was quoted as saying.